Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (AML) in adults. This marks the completion of the first adult dose cohort, a significant milestone that allows the company to advance to higher doses and initiate a pediatric trial, addressing critical unmet needs in AML treatment. The trial aims to assess safety and gather data on key endpoints, with encouraging early results showing patient survival at six and three months post-treatment.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 36,112
Technical Sentiment Signal: Sell
Current Market Cap: £6.41M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.